Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Research Articles

Herbal Compound Farnesiferol C Exerts Antiangiogenic and Antitumor Activity and Targets Multiple Aspects of VEGFR1 (Flt1) or VEGFR2 (Flk1) Signaling Cascades

Jae-Ho Lee, Sun Choi, Yoonji Lee, Hyo-Jeong Lee, Kwan-Hyun Kim, Kyoo-Seok Ahn, Hyunsoo Bae, Hyo-Jung Lee, Eun-Ok Lee, Kwang-Seok Ahn, Shi Yong Ryu, Junxuan Lü and Sung-Hoon Kim
Jae-Ho Lee
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sun Choi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yoonji Lee
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hyo-Jeong Lee
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kwan-Hyun Kim
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kyoo-Seok Ahn
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hyunsoo Bae
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hyo-Jung Lee
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eun-Ok Lee
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kwang-Seok Ahn
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shi Yong Ryu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Junxuan Lü
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sung-Hoon Kim
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1535-7163.MCT-09-0775 Published February 2010
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Additional Files
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    A, structure of FC. B, cytotoxic effect of FC on HUVECs under nonproliferative conditions. HUVEC cells were exposed to FC in M199 medium containing 5% FBS (without heparin and growth factors) for 24 h and the proportion of metabolically viable cells was assessed by the XTT assay. Mean ± SEM, n = 3. ***, P < 0.01; ***, P < 0.001 compared with control. C, effect of FC on VEGF-induced tube formation (18-h stimulation in the absence or presence of FC). Data in graph were presented as mean ± SEM, n = 5 fields. ###, P < 0.001 compared with basal control; ***, P < 0.001 compared with VEGF-stimulated group. D, effect of FC on VEGF-A (10 ng/mL)–induced proliferation of HUVECs for 48 h. The relative number of metabolically viable cells were estimated by the XTT assay. Data were means ± SEM, n = 3 independent wells. ###, P < 0.001 compared with basal control; *, P < 0.05 compared with VEGF-stimulated group.

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    A, effect of FC on VEGF-induced cell motility (wound-healing test). Confluent HUVEC monolayers on 0.1% gelatin-coated six-well plates were scratch wounded. The cells were treated with various concentrations of FC in M199 with 5% FBS, 10 ng/mL VEGF, and 5 units/mL heparin for 16 h. Representative fields were photographed, ×100 magnification. Graph shows the quantitative effect of FC on VEGF-induced HUVEC motility. Data were presented as mean ± SEM, n = 3 wells. ###, P < 0.001 compared with basal control; **, P < 0.01; ***, P < 0.001 versus VEGF-stimulated group. B, effect of FC on VEGF-induced invasion of HUVEC through Matrigel in 12 h. Data were presented as means ± SEM n = 3 wells. ###, P < 0.001 compared with basal control; **, P < 0.01 compared with VEGF-stimulated group. C, effect of FC on VEGF-induced MMP-2 secretion from HUVECs after 20 h examined by zymography. D, effect of FC on VEGF-induced vessel sprouting ex vivo from rat aortic segments. Rat aortic segments were cultured on Matrigel and treated with VEGF (20 ng/mL) in the absence or presence of FC for 6 d. Graph shows the endothelial sprouts counts as the relative ratio to VEGF-stimulated control as 100. Data were presented as mean ± SEM, n = 3 aortas. ##, P < 0.01 compared with basal control; *, P < 0.05 and **, P < 0.01 compared with VEGF-stimulated control.

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    Effect of FC on the in vivo growth of LLC allograft tumors in mice and on angiogenesis and proliferation indices. LLC cells (5 × 105) were injected s.c. into the right flank of C57BL/6 mice. After 5 d, mice were given i.p. injection of FC (0.1 mg/kg and 1 mg/kg) or PBS (control) once a day. A, body weights of mice. B, tumor growth over time. Mean ± SD, n = 10 mice per group. *, P < 0.05; **, P < 0.01; ***, P < 0.001 compared with control. C, CD34 index (angiogenesis). D, Ki67 index (proliferation), E, TUNEL index (apoptosis). *, P < 0.05; **, P < 0.01 compared with control. Mean ± SD, n = 10.

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4.

    A, effect of FC on the binding of VEGFR1 (Flt-1) and VEGFR2 (KDR/Flk-1) to immobilized VEGF. Data were presented as means ± SEM, n = 3. **, P < 0.01; ***, P < 0.001 compared with control. B, Western blot analyses of effect of FC on VEGFR-signaling kinases. HUVECs were pretreated with FC for 30 min and further stimulated with 10 ng VEGF/mL for 10 min. C, in vitro Src kinase activity of FC-treated HUVEC cells prepared as in B.

  • Figure 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5.

    The potential binding modes (poses) of FC at the active site of Src tyrosine kinase (A–C) and FAK (D–F) by docking simulation. A and D, hydrophobic pocket near the ATP-binding site in Src and FAK, respectively. Connolly surface was generated for the protein by MOLCAD and colored by cavity depth, in which orange means deep cavity of the hydrophobic pocket. B and C, two possible binding modes of FC in Src. E and F, two possible binding modes of FC in FAK. FC is displayed in ball-and-stick and its carbon colors are magenta/purple in Src and orange/white in FAK, respectively. The Connolly surface was Z-clipped and the nonpolar hydrogen atoms are not displayed for clarity. Hydrogen bonds are displayed as yellow dashed lines and the participating residues are marked.

Additional Files

  • Figures
  • Supplementary Data, Lee et al.

    Files in this Data Supplement:

    • Supplementary Figures 1-4
PreviousNext
Back to top
Molecular Cancer Therapeutics: 9 (2)
February 2010
Volume 9, Issue 2
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Herbal Compound Farnesiferol C Exerts Antiangiogenic and Antitumor Activity and Targets Multiple Aspects of VEGFR1 (Flt1) or VEGFR2 (Flk1) Signaling Cascades
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Herbal Compound Farnesiferol C Exerts Antiangiogenic and Antitumor Activity and Targets Multiple Aspects of VEGFR1 (Flt1) or VEGFR2 (Flk1) Signaling Cascades
Jae-Ho Lee, Sun Choi, Yoonji Lee, Hyo-Jeong Lee, Kwan-Hyun Kim, Kyoo-Seok Ahn, Hyunsoo Bae, Hyo-Jung Lee, Eun-Ok Lee, Kwang-Seok Ahn, Shi Yong Ryu, Junxuan Lü and Sung-Hoon Kim
Mol Cancer Ther February 1 2010 (9) (2) 389-399; DOI: 10.1158/1535-7163.MCT-09-0775

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Herbal Compound Farnesiferol C Exerts Antiangiogenic and Antitumor Activity and Targets Multiple Aspects of VEGFR1 (Flt1) or VEGFR2 (Flk1) Signaling Cascades
Jae-Ho Lee, Sun Choi, Yoonji Lee, Hyo-Jeong Lee, Kwan-Hyun Kim, Kyoo-Seok Ahn, Hyunsoo Bae, Hyo-Jung Lee, Eun-Ok Lee, Kwang-Seok Ahn, Shi Yong Ryu, Junxuan Lü and Sung-Hoon Kim
Mol Cancer Ther February 1 2010 (9) (2) 389-399; DOI: 10.1158/1535-7163.MCT-09-0775
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosure of Potential Conflicts of Interest
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • PX-478 Radiosensitization in Pancreatic Cancer
  • Metronomic Gemcitabine Inhibits Pancreatic Cancer
  • p53-Deficient Cells Are More Sensitive to Plk1 Inhibitor
Show more Research Articles
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement